Haleon PLC Sponsored ADR $HLN Shares Acquired by Hantz Financial Services Inc.

Hantz Financial Services Inc. grew its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 11.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 698,267 shares of the company’s stock after purchasing an additional 69,818 shares during the period. Hantz Financial Services Inc.’s holdings in Haleon were worth $7,059,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of HLN. Bank of America Corp DE increased its holdings in shares of Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares during the period. Optiver Holding B.V. acquired a new position in shares of Haleon in the third quarter valued at about $45,593,000. JPMorgan Chase & Co. increased its holdings in shares of Haleon by 36.6% in the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after purchasing an additional 3,207,986 shares during the period. ABC Arbitrage SA increased its holdings in shares of Haleon by 159.4% in the third quarter. ABC Arbitrage SA now owns 2,727,350 shares of the company’s stock valued at $24,464,000 after purchasing an additional 1,675,889 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in shares of Haleon by 3,548.4% in the second quarter. BNP Paribas Financial Markets now owns 1,684,968 shares of the company’s stock valued at $17,473,000 after purchasing an additional 1,638,784 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HLN. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Finally, Argus raised Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Haleon has a consensus rating of “Moderate Buy” and a consensus target price of $13.40.

Haleon Stock Up 0.2%

Haleon stock opened at $9.30 on Tuesday. The firm has a market cap of $41.30 billion, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 2.12 and a beta of 0.15. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42. The business’s 50-day moving average price is $9.63 and its 200 day moving average price is $9.97. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47.

Haleon (NYSE:HLN) last posted its earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The company had revenue of $3.65 billion for the quarter. As a group, sell-side analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current year.

Haleon Announces Dividend

The business also recently announced a dividend, which was paid on Thursday, May 14th. Investors of record on Friday, April 10th were issued a dividend of $0.1307 per share. This represents a yield of 266.0%. The ex-dividend date of this dividend was Friday, April 10th. Haleon’s dividend payout ratio (DPR) is 64.10%.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.